Title: "Antipruritic Effect of the Long-Acting Peripheral Kappa Opioid Receptor Agonist CR845: A Novel Approach for the Treatment of Uremic Pruritus in Hemodialysis Patients"
Abstract Number: 3421
Location: Exhibit Hall,
Both posters will be on display
For more information on Kidney Week 2016, visit: https://www.asn-online.org/education/kidneyweek/.
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In a human abuse liability trial, I.V. CR845 demonstrated statistically significant reductions in "drug liking," "feeling high," "overall liking," and "take drug again" scores in comparison to I.V. pentazocine, a Schedule IV analgesic.
An oral formulation of CR845 is currently being evaluated in a Phase 2b study in osteoarthritis patients and was shown in a Phase 2a study to be well tolerated with twice a day dosing for two weeks, with evidence of decreasing pain scores during that time period.
In approximately 1,150 subjects dosed to date, CR845 was found to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists.
Steve SilverStern Investor Relations 212-362-1200 firstname.lastname@example.org MEDIA CONTACT: Annie Starr6 Degrees 973-415-8838 email@example.com
News Provided by Acquire Media